Effectiveness of probiotic K10 in managing health outcomes in Parkinson's and Alzheimer's disease

ISRCTN ISRCTN13536327
DOI https://doi.org/10.1186/ISRCTN13536327
Secondary identifying numbers 202301
Submission date
19/08/2023
Registration date
22/08/2023
Last edited
28/07/2025
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
We developed a clinical trial prior to this one, where we used the probiotic K10 in patients with Alzheimer's disease and obtained excellent results, so we decided to expand the number of patients in a new study, and also include another neurological disease, in this case Parkinson’s disease.

Who can participate?
Adult patients with Parkinson's or Alzheimer's disease.

What does the study involve?
This clinical trial will have 4 arms, being divided into two groups, group 1 with Alzheimer's and group 2 with Parkinson's, one arm of each group will receive probiotic K10 and one arm of each group will receive a controlled placebo.
The main objective of this study is to compare its effect with placebo on cognitive status in individuals with AD and PD, the UPDRS total score in people with early PD and quality of life, and the measurement of caregiver burden in AD and PD. Participants will be randomly assigned to receive a placebo (an inactive substance) and a K10 probiotic (30,000,000 CFU/day). They will be evaluated at baseline, 45 days and 90 days.

What are the possible benefits and risks of participating?
Not provided at time of registration

Where is the study run from?
Gon1 gestora de projetos (Brazil)

When is the study starting and how long is it expected to run for?
July 2023 to December 2023

Who is funding the study?
1. Micillic Ltd. (Portugal)
2. Gon1 Gestora de Projetos Ltda (Brazil)

Who is the main contact?
Deivis Oliveira Guimaraes
deivis.guimaraes@gon1.com.br

Study website

Contact information

Mr Deivis Oliveira Guimaraes
Public

Avenida Nossa senhora dos navegantes, 955
sala 719
Vitória
29050335
Brazil

ORCiD logoORCID ID 0009-0003-8970-5778
Phone +55 027 999429900
Email Deivis.guimaraes@gon1.com.br
Dr Alyne Mendonça Marques Ton
Principal Investigator

Avenida Nossa senhora dos navegantes, 955
sala 719
Vitória
29050335
Brazil

ORCiD logoORCID ID 0000-0002-0128-2746
Phone +55 027 98134-7065
Email lyne_msv@hotmail.com

Study information

Study designSingle-centre double-blind placebo-controlled randomized parallel trial
Primary study designInterventional
Secondary study designRandomised parallel trial
Study setting(s)University/medical school/dental school, Workplace
Study typeTreatment, Efficacy
Participant information sheet No participant information sheet available
Scientific titleEffectiveness of a Probiotic K10 in managing health outcomes in Parkinson’s disease and in early stage (mild cognitive impairment to mild dementia) Alzheimer’s disease
Study acronymK10 PK & AD
Study objectivesEvaluation of the effects of the K10 probiotic mix in patients with degenerative neurological diseases (Parkinson's and Alzheimer's) with a focus on cognitive, motor and psychiatric neurological evaluation.
Ethics approval(s)

Approved 27/07/2023, Universidade Vila Velha - ES/UVV (Avenida Comissário José Dantas de Melo, 21, Vila Velha, 29102-920, Brazil; +55 (27) 3421-2063; cep@uvv.br), ref: 6.202.959

Health condition(s) or problem(s) studiedImprovement of symptoms in patients with Parkinson's and Alzheimer's disease
InterventionIn this study, researchers will conduct a randomized, placebo-controlled, phase III trial of a probiotic preparation (Probiotic K10) to evaluate its use as a viable treatment option for neurodegenerative disorders, including Parkinson's disease (PD) and Alzheimer's disease. of Alzheimer (AD). This formulation has been previously demonstrated to improve cognitive function, systemic inflammation, systemic oxidative stress in Alzheimer's patients. The main objective of this study is to compare its effect with placebo on cognitive status in individuals with AD and PD, the UPDRS total score in people with early PD and quality of life, and the measurement of caregiver burden in AD and PD.

Participants will be randomly assigned to receive a placebo (an inactive substance) and a K10 probiotic (30,000,000 CFU/day). They will be evaluated at baseline, 45 days and 90 days.
Randomization using an online tool: https://ctrandomization.cancer.gov/tool/
Intervention typeSupplement
Primary outcome measure1. Parkinson's group
1.1. Parkinson's Disease rating scale (MDS- UPDRS) at baseline visit, 45 days and 90 days or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first.
1.2. PD quality of life scale (PDQ-39) at baseline visit, 45 days and 90 days or the time of sufficient disability to require dopaminergic therapy or study closure.
1.3. Anxiety levels, mood and caregiver burden in neuropsychiatric evaluation from baseline to T90 or the time of sufficient disability to require dopaminergic therapy or study closure.

2. Alzheimer's group
2.1. Cognitive status measured by brief battery focused on evaluating memory, visuo-spatial skills, constructive skills, language, praxys and attention.
at baseline visit, 45 days and 90 days.
2.2. DA Quality of Life Scale baseline visit, 45 days and 90 days.
2.3. Anxiety levels, mood and caregiver burden in neuropsychiatric evaluation from baseline to T90 or the time of sufficient disability to require dopaminergic therapy or study closure.
Secondary outcome measuresIndirect measurement of emotional stress measured by urinary cortisol dosage at baseline visit, 45 days and 90 days.
Overall study start date27/07/2023
Completion date11/12/2023

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
Upper age limit85 Years
SexBoth
Target number of participants104
Total final enrolment166
Key inclusion criteriaParkinson's arm
1. Presence of all 3 cardinal features of Parkinson's disease (tooth tremor, bradykinesia, and rigidity). Clinical signs must be asymmetrical.
2. Diagnosis of Parkinson's disease within 5 years of the Screening Visit.
3. Age 18 years or older.
4. Women must not be of childbearing potential or must use an approved form of contraception during the trial period.

Alzheimer's arm
1. Men or women between the ages of 60 and 85
2. Diagnosis of probable Alzheimer's disease
3. Portuguese-speaking, English-speaking; Spanish-speaking if the individual site allows
4. Study partner or caregiver to ensure compliance
5. Mini-Mental State Exam score at screening visit greater than 14
6. Stable medical condition for 3 months prior to screening, with no significant abnormal liver, kidney, or blood studies.
7. Able to take oral medications
8. Modified Hachinski Ischemic Index less than or equal to 4
9. CT or MRI from the onset of memory impairment, demonstrating the absence of a clinically significant focal lesion
10. Physically acceptable for this study, as confirmed by medical history, physical examination, neurological examination, and clinical testing
Key exclusion criteriaParkinson's arm:
1. Parkinsonism due to drugs including neuroleptics, alpha-methyldopa, reserpine, metoclopramide, valproic acid.
2. Use of antioxidants (such as selegiline, rasagiline, vitamins E and C), additional supplemental vitamins or minerals, regular use of neuroleptics, chloramphenicol, valproic acid, warfarin.
3. Other parkinsonian disorders.
4. Modified Hoehn and Yahr score of 3 or more on Screening Visit or Baseline Visit.
5. UPDRS tremor score of 3 or greater at Screening Visit or Baseline Visit.
6. History of symptomatic stroke.
7. Sufficient deficiency to require changes in dopaminergic medication treatment during follow-up compared to baseline treatment schedule.
8. Other severe and uncompensated illnesses, including severe psychiatric illnesses.
9. Patients with active cardiovascular, restrictive peripheral vascular, or cerebrovascular disease in the past year.
10. Unstable dose of active CNS therapies.
11. Use of appetite suppressants within 60 days of the Baseline Visit.
12. History of active epilepsy within the past 5 years.
13. Participation in other drug studies or use of other investigational drugs within 30 days prior to the Screening Visit.
14. History of electroconvulsive therapy.
15. History of any brain surgery for Parkinson's disease.
16. History of structural brain disease, such as previous trauma causing damage detected on a CT scan or MRI, hydrocephalus, or previous brain neoplasms.

Alzheimer's arm:
1. Significant neurological disease such as Parkinson's disease, stroke, brain tumor, multiple sclerosis, or seizure disorder
2. Major depression treated in the past 12 months, major mental illness such as schizophrenia, or recent (in past 12 months) alcohol or substance abuse
3. History of invasive cancer within the past two years (excluding non-melanoma skin cancer)
4. Use of any investigational agents within 30 days prior to screening
5. Major surgery within 8 weeks prior to the Baseline Visit
6. Uncontrolled cardiac conditions or severe unstable medical illnesses
7. Antiretroviral therapy for human immunodeficiency virus (HIV)
8. Conditions that will contribute to oxidative stress: current cigarette or cigar smokers (within past month), diabetics on insulin or poorly controlled on oral hypoglycemics
9. Blindness, deafness, language difficulties or any other disability which may prevent the participant from participating or cooperating in the protocol.
Date of first enrolment28/07/2023
Date of final enrolment10/08/2023

Locations

Countries of recruitment

  • Brazil

Study participating centre

Gon1 gestora de projetos
Av. Nossa Senhora dos Navegantes, 955
sala 719
Vitória
29050335
Brazil

Sponsor information

Micillic Ltd.
Other

Avenida Arriaga, 73
Escritório 105
Ilha da Madeira
9000-064
Portugal

Phone +351 938 259 609
Email andre@vermiliongroup.org
Website https://www.micillic.pt

Funders

Funder type

Industry

Micillic Ltd.

No information available

Gon1 Gestora de Projetos Ltda

No information available

Results and Publications

Intention to publish date20/12/2024
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal
IPD sharing planThe data collected from the volunteers will not be disclosed anonymously in order to preserve the identity and confidentiality defined in the research consent term, the collected data being identified by random numbers and stored on their own servers in an encrypted folder, in case of interest of Access to the data can be requested through the email adm@gon1.com.br or at https://gon1.com.br/ipd and it is mandatory to present a technical justification and complete identification of the requester.

Editorial Notes

28/07/2025: Internal review.
22/08/2023: Trial's existence confirmed by Universidade Vila Velha - ES/UVV.